About
Gentian Diagnostics is a Norwegian in vitro diagnostics (IVD) company established in 2001. The company specializes in developing and manufacturing high-quality diagnostic reagents using immunochemistry. Gentian focuses on particle-enhanced turbidimetric immunoassays (PETIA), which transform clinically relevant biomarkers into efficient, automated assays for clinical chemistry analyzers. This technology enhances laboratory efficiency and patient outcomes by enabling faster and cost-effective diagnostic testing. Gentian offers a range of tests targeting major disease areas such as infections, inflammation, kidney failure, and congestive heart failure. Their product lineup includes established tests like Cystatin C, fCAL® turbo, Canine CRP, fPELA turbo, and GCAL®, with additional products in development. The company serves both human and veterinary diagnostics markets globally, with a presence in Europe, the USA, and China. Gentian's assays are compatible with major clinical chemistry platforms, allowing laboratories to integrate new tests seamlessly. The company is headquartered in Moss, Norway, and continues to grow its market share through innovative technology and a strong product pipeline.
Technologies
Keywords
Company Information
-
Employees 63
-
Founded 2001
-
Annual Revenue $13430000
Location
Moss, Viken, Norway
